An interventional study of Experimental: Dual-Language Dysarthria Self-Assessment and Management Software (D-SAMS) in Dysarthria, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Superior University · Not applicable, Interventional, and Supportive care
The research focuses on the development of a dual-language (Urdu and English) digital software designed for the self-assessment and management of adult dysarthria patients. Dysarthria, a motor speech disorder resulting from neurological injury, significantly affects an individual's ability to communicate effectively.
Current assessment tools are often clinician-dependent and predominantly available in English, limiting accessibility for non-English speakers, especially in Pakistan and other Urdu-speaking regions. This study aims to bridge that gap by creating a user-friendly, culturally relevant, and linguistically accessible software platform. The software will enable adult dysarthric patients to monitor their speech abilities, track progress, and participate more actively in their therapy process. It is expected to enhance patient autonomy, improve communication outcomes, and support speech-language pathologists in delivering more efficient care. The dual-language interface ensures broader usability, promoting inclusion and better engagement among diverse user groups in bilingual settings.
60 studies on the registry are indexed under Dysarthria; 19 are open to participants now.
This study's enrollment of 50 is above the median of 39 across 44 interventional studies indexed under Dysarthria.
Browse Dysarthria studies →Superior University is the lead sponsor of 253 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
D-SAMS is a bilingual (Urdu and English) digital tool designed for adult dysarthria patients. It enables users to assess their speech through interactive tasks (e.g., repetition, reading, and pronunciation exercises), receive feedback, and track progress over time. The software includes audio-visual prompts, self-rating scales, and progress charts, and is tailored to accommodate varying levels of dysarthria severity. It supports independent practice and helps speech-language pathologists monitor patients remotely
Combination Product: Experimental: Dual-Language Dysarthria Self-Assessment and Management Software (D-SAMS)
D-SAMS is a bilingual (Urdu and English) digital tool designed for adult dysarthria patients. It enables users to assess their speech through interactive tasks (e.g., repetition, reading, and pronunciation exercises), receive feedback, and track progress over time. The software includes audio-visual prompts, self-rating scales, and progress charts, and is tailored to accommodate varying levels of dysarthria severity. It supports independent practice and helps speech-language pathologists monitor patients remotely
Frenchay Dysarthria Assessment (FDA-2)
Assesses: Motor speech function. Scoring: A (normal) to E (severely impaired) across speech subsystems.
Time frame: 24 Months
Dysarthria Impact Profile (DIP)
Assesses: Psychosocial impact of dysarthria. Scoring: 48 items, rated 1-5; higher scores = greater negative impact.
Time frame: 24 Months
Speech Intelligibility Rating Scale (SIRS)
Assesses: Speech clarity. Scoring: 1 (unintelligible) to 5 (fully intelligible).
Time frame: 24 Months
Voice Handicap Index-10 (VHI-10) (optional)
Assesses: Patient's perception of voice issues. Scoring: 0-4 per item; total out of 40. Higher = more voice difficulty.
Time frame: 24 Months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.